The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac-Reference-Cited by-同舟云学术

The European Medicines Agency's use of prioritised independent research for best evidence in regulatory action on diclofenac

Published:2014-02-25 Issue:4 Volume:23 Page:431-434
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Arlett Peter¹,Sarac Sinan B.²,Thomson Andrew³,Davies Claire³,Teixeira Tania¹,Blake Kevin V.¹,Stenver Doris²

Affiliation:

1. European Medicines Agency; London UK

2. Danish Health and Medicines Authority; Copenhagen Denmark

3. Medicines and Healthcare products Regulatory Agency; London UK

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Reference12 articles.

1. tEuropean Medicines Agency Benefit-risk methodology http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000314.jsp&mid=WC0b01ac0580665b63

2. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude;Ehmann;Clin Pharmacol Ther,2013

3. Advancing the science of medicines regulation: the role of the 21st-century medicines regulator;Lumpkin;Clin Pharmacol Ther,2012

4. Increasing scientific standards, independence and transparency in post-authorisation studies: the role of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance;Blake;Pharmacoepidem Drug Saf,2012

5. The pharmacoepidemiological research on outcomes of therapeutics by a European Consortium (PROTECT) project http://www.imi-protect.eu/

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions;Pharmaceutical Medicine;2022-07-03

2. Role of Real World Data in Pharmacoepidemiology Research: From Single Database Towards Global Collaboration;Databases for Pharmacoepidemiological Research;2021

3. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012;Expert Opinion on Drug Safety;2020-03-31

4. Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?;Clinical Pharmacology & Therapeutics;2018-10-14

5. Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP);Pharmacoepidemiology and Drug Safety;2018-01-11